Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Baker Bros. Advisors and related persons report beneficial ownership of 9,364,972 shares of Revolution Medicines, Inc. common stock, representing 5.0% of 186,901,268 shares outstanding as of June 30, 2025. The holdings are held through two funds: 667, L.P. (0.4%) and Baker Brothers Life Sciences, L.P. (4.6%). The filing states the Adviser has sole voting and dispositive power over the funds' securities under management agreements and that certain prefunded warrants exist but cannot currently be exercised because of a 4.99% ownership cap on exercise.
Janus Henderson Group plc reports a passive, non-controlling stake in Revolution Medicines common stock, with disclosed shared voting and dispositive power in the range of 10.45–10.59 million shares, representing about 5.6%–5.7% of the class. The filing identifies both a group-level beneficial figure of 10,590,727 shares (5.7%) and a related subsidiary position of 10,445,374 shares (5.6%), indicating Janus Henderson exercises shared voting and disposition rights over these holdings.
The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power-of-attorney authorizing compliance signatories to execute and amend related ownership reports on the company's behalf.
Revolution Medicines (RVMD) filed a Form 4 for director Alexis Borisy covering transactions on 26 June 2025.
- 3,142 Restricted Stock Units (RSUs) were acquired at no cost, lifting his direct common-stock position to 2,338,884 shares.
- A new stock-option grant for 11,574 shares was issued at an exercise price of $37.48, expiring on 26 Jun 2035; the award vests in full on the earlier of the first anniversary or the next annual meeting, assuming continued service.
No shares were sold, so Mr. Borisy’s net exposure to RVMD equity increased. Although the incremental RSU amount is small relative to his existing 2.3 million-share stake, the at-the-money option grant and additional RSUs reinforce alignment between the director and shareholders by incentivizing future price appreciation.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
